Epidemiology and impact of Chronic Obstructive Pulmonary Disease (COPD) globally.



Cherian Varghese MD., Ph.D. Coordinator, Management of NCDs WHO, Geneva.













SDG targets





































3.4 By 2030, reduce by one third premature mortality from noncommunicable diseases through prevention and treatment and promote mental health and well-being

- 3.8 Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all
- 3.8.1 Coverage of essential health services (defined as the average coverage of essential services based on tracer interventions that include reproductive, maternal, newborn and child health, infectious diseases, non-communicable diseases and service capacity and access, among the general and the most disadvantaged population)
- **3.8.2** Number of people covered by health insurance or a public health system per 1,000 population













Four types of NCDs are largely preventable by means of effective interventions that tackle shared modifiable risk factors

		Tobacco use	Unhealthy diets	Physical inactivity	Harmful use of alcohol	Air pollution
Non-co	Heart disease and stroke					
Non-communicable diseases	Diabetes	√			√	
	Cancer	√	√	√	√	
	Chronic lung disease	√				
	Mental health					•













Chronic obstructive pulmonary disease (COPD)

- Is a progressive life threatening lung disease that causes breathlessness (initially with exertion) and predisposes to exacerbations and serious illness.
- More than 90% of COPD deaths occur in low and middleincome countries.
- The primary cause of COPD is exposure to tobacco smoke (either active smoking or secondhand smoke).
- Other risk factors include exposure to indoor and outdoor air pollution and occupational dusts and fumes.
- Exposure to indoor air pollution can affect the unborn child and represent a risk factor for developing COPD later in life.
- Some cases of COPD are due to long-term asthma.
- COPD is likely to increase in coming years due to higher smoking prevalence and aging populations in many countries.





















ELSEVIER Leading causes 1990		Leading causes 2007	Mean percentage change in number of YLLs, 1990-2007	Mean percentage change in all-age YLL rate, 1990-2007	Mean percentage change in age standardised YLL rate, 1990-2007		Leading causes 2017	,
					1	pi i		
1 Neonatal disorders		1 Neonatal disorders	-21.2	-37⋅2	-20.7		1 Ischaemic heart dis	sease
2 Lower respiratory infections		2 Lower respiratory infections	-38.6	-51.0	-41.1		2 Neonatal disorders	s
3 Diarrhoeal diseases		3 Ischaemic heart disease	20.9	-3.6	-20.2	" many	3 Stroke	
4 Ischaemic heart disease		4 Diarrhoeal diseases	-39·5	-51.8	-42.6		4 Lower respiratory in	nfection
5 Stroke	******	5 HIV/AIDS	419.0	313.7	316∙4		5 Diarrhoeal disease	s
6 Congenital anomalies		6 Stroke	12.9	-10.0	-24.0		6 Road injuries	
7 Tuberculosis	in V	7 Malaria	30.1				7 COPD	
8 Road injuries	·. A	8 Road injuries	1.3	-19-3	-18-4		8 HIV/AIDS	
9 Measles	/1/	9 Congenital anomalies	-18-3	-34-9	-19-1	/	9 Congenital anoma	alies
10 Malaria		10 Tuberculosis	-19·1	-35.6	-38-2		10 Malaria	
11.0	. /						Tuberculosis	
7							cancer	
		C.D.L. C.		_			osis	

The Global Burden of Disease Study reports a prevalence of 251 million cases of COPD globally in 2016.

Globally, it is estimated that 3.17 million deaths were caused by the disease in 2015 (that is, 5% of all deaths globally in that year).

tein-energy malnutrition

nic kidney disease

personal violence

imer's disease

ower respiratory infections

narm

etes

cancer

ngitis ning

· 39 Measles

neonatal, and nutritional diseases Non-communicable diseases

Injuries

Mean

change

number of YLLs,

2007-17

17.3

-24.1

12.1

-25.9

-32.0

-9.7

13.2

-51.2

-15.3

-34.5

-21.2

24.8

8.9

-3.4

29.9

21.0

38.6

-1.6

21.2

-25.2

percentage

Mean

change in all-age

YLL rate,

2007-17

3.9

-32.8

-0.7

-34.4

-39.8-20.0

0.3

-56.8

-25.0

-42.0

-30.2

10.6

-3.5

-14.4

15.0

7.2

22.8

-12.9

-33.7

Communicable, maternal,

7.4

percentage

Mean

percentage change in age-

YLL rate,

2007-17

standardised

-9.8

-26.2

-13.8

-32.6

-38.1

-19.6

-14.3

-56.6

-18.8

-39.2

-33.3

-4.1

-11.3

-15.1

0.7

-2.5

-0.3

-10.9

-4.6

-30.2

30 Liver cancer



24 Liver cancer










Global prevalence of asthma and COPD, persons, 1990 – 2016, age-standardised

Prevalence, %


















Global death rate due to asthma and COPD, persons, 1990 – 2016, age-standardised

Deaths, rate per 100k


















Global YLD due to asthma and COPD, persons, 1990 - 2016

YLDs (Years Lived with Disability), rate per 100k



















RISK FACTORS
















The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2016. All rights reserved.

Data Source: World Health Organization
Map production: Information Evidence and Research (IER)
World Health Organization
















Deaths attributable to household air pollution, 2016



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization
Map Production: Information Evidence and Research (IER)
World Health Organization


















Mean Body Mass Index (kg/m2), ages 18+, 2016 (age standardized estimate) Female



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization
Map Production: Information Evidence and Research (IER)
World Health Organization




© WHO 2017. All rights reserved.
















IMPACT





























Higher Rates of <u>Hospitalisation</u> Due to Comorbidities in COPD



Reproduced with permission of *Chest*, from "Comorbidity and Mortality in COPD Related Hospitalizations in the United States, 1979 to 2001," Holguin F et al, Vol 128, pp 2005-2011, Copyright © 2005.















COPD

Total national cost (Euro/year):

1999: 1.1 billion

2010: 1.5 billion

Jansson SA, et al, Chest 2002 Jansson SA et al, Resp Med 2013

2018-09-16 Anders Lindén















ACTION













The world is off-track to deliver its commitments on NCDs

Have countries strengthened their capacities to address NCDs since 2011?

Yes

Have there been improvements in NCD health outcomes since 2011?

Yes, but...

Are we on track to meet the commitments made at the UN General Assembly?

No

Are we on track to meet SDG Target 3.4 (NCDs) by 2030?

No






2018: "It's crucial to reach agreements on a new strategic course and approach to support countries in implementing the best buys for NCDs"

n Je la Salud

Raise taxes on tobacco, 2014



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization Map Production: Health Statistics and Information Systems (HSI) World Health Organization




© WHO 2015. All rights reserved.





























Interventions to reduce indoor air pollution from solid fuels

Source of Pollution	Home environment	User Behaviour
-Improved Stoves -Cleaner Fuels (Kerosene, Gas, Electricity)	-Hoods and Chimneys -Windows, Ventilation holes, eaves spaces -Separate Kitchen	-Fuel drying -Use of Pot lids -Good maintenance -Keeping children away from smoke



Max CO in households of highlanders before and after 2 month of Installations New Clean stoves















Manage chronic respiratory diseases

'Effective interventions with CEA >I\$100 per DALY averted in LMICs







Other recommended interventions from WHO quidance (CEA not available)



Symptom relief for patients with asthma with inhaled salbutamol

Symptom relief for patients with chronic obstructive pulmonary disease with inhaled salbutamol

Treatment of asthma using low dose inhaled beclometasone and short acting beta agonist

Access to improved stoves and cleaner fuels to reduce indoor air pollution

Cost-effective interventions to prevent occupational lung diseases, for example, from exposure to silica, asbestos

Influenza vaccination for patients with chronic obstructive pulmonary disease













OUR POLICY IS PATIENT CENTRED CARE, SO YOU HAVE TO FILL OUT FORMS, AB6-12, MR7-9 AND XE113.





Standardized protocols
Operational at primary care
Availability of peak flow meters
Access to medicines
Patient education

CHAT scan

just chat with the person!















GLOBAL ALLIANCE AGAINST CHRONIC RESPIRATORY DISEASES

HOME

ABOUT GARD

COUNTRIES

MEETINGS & EVENTS

RESOURCES

GALLERY

PUBLICATIONS

CONTACT US

Q

12th GARD General Meeting Aug 29 - Sept 1, 2018



Click here for registration and hotel accommodation







of #pollen and fungal spore monitoring stations around the world in a review published at #CTA_journal and see where your country stands ctajournal.biomedcentral.com/article s/10.11...















